Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease

Human Immunology

Volumn 71, Issue 9, 2010, Pages 874-877

  Brugos, Boglarka ^a   Kiss, Emese ^a   Dul, Csaba ^b   Gubisch, Wolfgang ^c   Szegedi, Gyula ^a   Sipka, Sandor ^a   Zeher, Margit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Biomedica Gruppe   (Hungary)

^c Biomedica Gruppe   (Austria)

Author keywords

Active SLE; Creatinine clearance; Interleukin 1 receptor antagonist; Lupus nephritis; Methylprednisolone

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NUCLEOSOME; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; METABOLIC CLEARANCE RATE; METHYLPREDNISOLONE; MIDDLE AGED; PROTEINURIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77954473988     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.06.004     Document Type: Article

References (30)

1. Alheim K., Bartfai T. The interleukin-1 system: Receptors, ligands and ICE in the brain and their involvement in the fever response. Ann NY Acad Sci 1998, 840:51-58.
2. Bresnihan B., Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 1998, 24:615-628.
3. Arend W. Interleukin 1 receptor antagonist. J Clin Invest 1991, 88:1445-1451.
4. Dinarello C. The interleukin-1 family: 10 Years of discovery. FASEB J 1994, 8:1314-1325.
5. Kanangat S., Postlethwaite A., Higgins G., Hasty K. Novel function of intracellular IL-1Ra in human dermal fibroblasts: Implications in the pathogenesis of fibrosis. J Invest Dermatol 2006, 126:756-765.
6. Malyak M., Smith M.J., Abel A., Hance R., Arend W. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol 1998, 161:2004-2010.
7. Sturfelt G., Roux-Lombard P., Wollheim F., Dayer J. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997, 36:1283-1289.
8. Aringer M., Smolen J. Cytokine expression in lupus kidneys. Lupus 2005, 14:13-18.
9. Tsokos G. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1995, 7:376-383.
10. Mok C., Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003, 56:481-490.
11. Kyttaris V., Krishnan S., Tsokos G. Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity 2006, 39:705-709.
12. Aringer M., Smolen J. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: A rationale for therapeutic intervention. Lupus 2004, 13:344-347.
13. Tesch G.H., Lan H.Y., Atkins R.C., Nikolic-Paterson D.J. Role of interleukin-1 in mesangial cell proliferation and matrix deposition in experimental mesangioproliferative nephritis. Am J Pathol 1997, 151:141-150.
14. Matsukawa A., Fukumoto T., Maeda T., Ohkawara S., Yoshinaga M. Detection and characterization of IL-1 receptor antagonist in tissues from healthy rabbits: IL-1 receptor antagonist is probably involved in health. Cytokines 1997, 9:307-315.
15. Blakemore A.I., Tarlow J.K., Cork M.J., Gordon C., Emery P., Duff G.W. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994, 37:1380-1385.
16. Suzuki H., Takemura H., Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 1995, 38:1055-1059.
17. Kiberd B.A., Stadnyk A.W. Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule?. J Immunopharmacol 1995, 30:131-137.
18. McBride W.T., Allen S., Gormley S.M., Young I.S., McClean E., MacGowan S.W., et al. Methylprednisolone favourably alters plasma and urinary cytokine homeostasis and subclinical renal injury at cardiac surgery. Cytokines 2004, 27:81-89.
19. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
20. Brugos B., Kiss E., Szodoray P., Szegedi G., Zeher M. Retrospective analysis of patients with lupus nephritis: Data from a large clinical immunological center in Hungary. Scand J Immunol 2006, 64:433-437.
21. Lewis E., Schwartz M. Pathology of lupus nephritis. Lupus 2005, 14:31-38.
22. Vitali C., Bencivelli W., Isenberg D., Smolen J., Snaith M., Sciuto M., et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients: European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992, 10:541-547.
23. Capper E., Maskill J., Gordon C., Blakemore A. Interleukin (IL-)-10, IL-1Ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: Could longitudinal studies reveal patient subgroups of differing pathology?. Clin Exp Immunol 2004, 138:348-356.
24. Becker G., Waldburger M., Hughes G. Value of serum C-reactive protein measurement in the investigation of fever in SLE. Ann Rheum Dis 1980, 39:50.
25. Liou L. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001, 19:515-523.
26. Liou L. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels. Clin Exp Rheumatol 2003, 21:437-444.
27. Buraczynska M., Ksiazek P., Kubit P., Zaluska W. Interleukin-1 receptor antagonist gene polymorphism affects the progression of chronic renal failure. Cytokines 2006, 36:167-172.
28. Allen J.N., Zhiming L., Wewers M.D., Altenberger E.A., Moore S.A., Allen E.D. Detection of IL-5 and IL-1 receptor antagonist in bronchoalveolar lavage fluid in acute eosinophilic pneumonia. J Allergy Clin Immunol 1996, 97:1366-1374.
29. Zwiech R., Kacpezyk F., Szuflet A., Nowicki M. Prognostic values of serum concentration and urinary excretion of interleukin-1 receptor antagonist and tumor necrosis factor receptors type I and II in patients with IgA nephropathy. Pol Arch Med Wewn 2005, 113:326-333.
30. Conti F., Breton S., Batteux F., Furlan V., Houssin D., Weill B., Calmus Y. Defective interleukin-1 receptor antagonist production is associated with resistance of acute liver graft rejection to steroid therapy. Am J Pathol 2000, 157:1685-1692.